Sarepta Therapeutics’ (SRPT) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $152.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on the company. Evercore ISI upgraded Sarepta Therapeutics from an in-line rating to an outperform rating and cut their price target for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Bank of America boosted their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a report on Friday, June 21st. Morgan Stanley reaffirmed an overweight rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. Finally, Leerink Partners boosted their target price on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an outperform rating in a report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has an average rating of Moderate Buy and a consensus price target of $187.39.

Sarepta Therapeutics Trading Down 1.9 %

Shares of SRPT stock opened at $124.79 on Friday. The firm has a fifty day moving average price of $136.71 and a 200-day moving average price of $132.78. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The company has a market cap of $11.80 billion, a price-to-earnings ratio of 1,134.45 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) EPS. As a group, equities analysts predict that Sarepta Therapeutics will post 1.47 earnings per share for the current year.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently made changes to their positions in the company. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $31,000. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. increased its holdings in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics in the first quarter worth approximately $32,000. Finally, Principal Securities Inc. purchased a new stake in Sarepta Therapeutics during the fourth quarter worth $26,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.